Serum magnesium and potassium in acute myocardial infarction: relationship to existing beta-blockade and infarct size

K Landmark1, P Urdal

  • 1Department of Internal Medicine, Ullevål University Hospital, Oslo, Norway.

Angiology
|May 1, 1993
PubMed

Insights

In acute myocardial infarction (AMI), initial drops in serum magnesium and potassium are linked to beta 2-adrenergic receptor stimulation. Nonselective beta-blockers can prevent these early changes in AMI patients.

Area of Science:

  • Cardiology
  • Biochemistry
  • Pharmacology

Background:

  • Acute myocardial infarction (AMI) is a critical cardiovascular event.
  • Electrolyte balance, specifically serum magnesium (s-Mg) and potassium (s-K), plays a vital role in cardiac function and response to AMI.
  • Early changes in s-Mg and s-K during AMI are not fully understood.

Purpose of the Study:

  • To investigate the temporal changes in serum magnesium and potassium levels in the early phase of acute myocardial infarction.
  • To explore the influence of time from chest pain onset to sample collection on these electrolyte levels.
  • To determine the effect of nonselective beta-blockers on these early electrolyte shifts in AMI patients.

Main Methods:

  • A cohort of 314 patients with AMI was divided into three groups based on the time of initial blood sampling (0-6, 6-10, and 10-24 hours post-chest pain onset).
  • Serum magnesium (s-Mg) and potassium (s-K) were measured in acute (s-Mg1, s-K1) and convalescent (s-Mg2, s-K2) samples.
  • Changes in electrolytes (delta s-Mg, delta s-K) were correlated with peak creatine kinase (CKmax) levels and beta-blocker use.

Main Results:

  • Serum Mg was lower in the initial sample (s-Mg1) compared to the later sample (s-Mg2) across all groups.
  • Serum K was reduced in the initial sample (s-K1) only in the earliest group (0-6 hours).
  • Nonselective beta-blockers attenuated the drop in s-Mg1 and completely inhibited the drop in s-K1 in the early AMI phase. Electrolyte changes correlated with CKmax levels.

Conclusions:

  • The initial decrease in serum magnesium and potassium during the early phase of AMI is likely mediated by increased beta 2-adrenergic receptor stimulation.
  • Nonselective beta-blockers can prevent or mitigate these early electrolyte changes in AMI patients.
  • These findings highlight the role of adrenergic activity in electrolyte shifts during AMI and the potential protective effect of beta-blockade.

Related Concept Videos

Heart Failure Drugs: Inotropic Agents01:26

Heart Failure Drugs: Inotropic Agents

Positive inotropic agents are commonly used as the first line of treatment for heart failure. One such agent is digoxin, derived from the genus Digitalis, which has been known for centuries but effectively utilized since 1785. However, these cardiac glycosides can have potentially toxic effects due to their mechanism of action, which involves inhibiting Na+/K+-ATPase and increasing contractility. Digoxin is absorbed orally and distributed in various tissues, including the CNS. It has a long...
Blood Studies for Cardiovascular System I: Cardiac Biomarkers01:20

Blood Studies for Cardiovascular System I: Cardiac Biomarkers

Cardiac biomarkers are enzymes, proteins, and hormones released into the blood when cardiac cells are injured. They are powerful tools for triaging.
The essential diagnostic tools for detecting myocardial necrosis and monitoring individuals suspected of having acute coronary syndrome (ACS) include:
Troponins
Troponins, particularly cardiac troponins I and T, are the most precise and sensitive markers of myocardial injury. They are detectable within 4-6 hours of myocardial injury and remain...
Myocarditis III: Medical Management01:14

Myocarditis III: Medical Management

Myocarditis: Comprehensive Medical ManagementMyocarditis, the heart muscle inflammation, requires a comprehensive medical management strategy that addresses the underlying cause, provides supportive care, manages symptoms, and reduces cardiac workload.Infections and Autoimmune CausesAdminister appropriate antimicrobial therapy when an infectious agent causes myocarditis. For instance, penicillin treats infections caused by Group A Streptococcus. In cases where autoimmune processes are...
Acute Coronary Syndrome I: Introduction01:30

Acute Coronary Syndrome I: Introduction

Acute Coronary Syndrome (ACS) encompasses a spectrum of heart conditions caused by sudden obstruction of coronary arteries, typically resulting from the rupture of an atherosclerotic plaque and subsequent thrombus (blood clot) formation. This obstruction can lead to partial or complete blockage of blood flow, causing varying degrees of myocardial ischemia or infarction.ACS includes the following clinical entities:Unstable Angina (UA)Non-ST-Elevation Myocardial Infarction (NSTEMI)ST-Elevation...
Acute Coronary Syndrome III: Diagnostic Studies01:30

Acute Coronary Syndrome III: Diagnostic Studies

Diagnosing acute coronary syndrome or ACS begins with a thorough patient history. Notable symptoms include central, crushing chest pain radiating to the left arm, neck, jaw, or back, along with shortness of breath, sweating (diaphoresis), nausea, vomiting, dizziness, and palpitations.It is crucial to note any history of cardiac illnesses and assess risk factors, including age, gender, smoking, hypertension, diabetes, hyperlipidemia, and a sedentary lifestyle.During physical examination, vital...